rAd-p53联合化疗及局部热疗治疗恶性浆膜腔积液  

rAd-p53 Combined with Chemotherapy and Local Thermotherapy for Patients with Malignant Serosal Cavity Effusion

作　　者：汪海岩[1] 赵利红[1] 张敬川[1] 许统俭[1] 韩秋裕[1] 于大海[2] 

机构地区：[1]徐州医学院附属医院,江苏徐州221006 [2]徐州市中心医院,江苏徐州221009

出　　处：《中国肿瘤》2012年第9期717-720,共4页China Cancer

摘　　要：[目的]探讨浆膜腔内灌注重组人p53腺病毒注射液(rAd-p53)及顺铂联合区域热疗治疗恶性浆膜腔积液的临床疗效及毒副作用。[方法]60例恶性浆膜腔积液患者随机分为2组,观察组30例每周腔内注射rAd-p532支(1×1012vp/支),72h后腔内再注入顺铂60mg,连用2周,1h后行局部热疗1h,热疗2次/周,共8次,4周后评价疗效及不良反应。对照组除不给予rAd-p53外,腔内化疗、热疗与观察组相同。[结果]观察组有效率(CR+PR)为86.7%,对照组为60.0%(P=0.01)。观察组生活质量改善率明显优于对照组(70%vs30%,P=0.006)。观察组治疗后免疫功能未受损害。观察组不良反应主要为自限性发热。[结论]腔内rAd-p53联合化疗及局部热疗控制恶性浆膜腔积液安全有效,疗效确切,同时可改善患者生活质量。[Purpose] To investigate the response and toxicity of intraperitoneal recombi- nant adenovirus p53 injection （rAd-p53） and cisplatin combined with local thermotherapy for malignant serosal cavity effusion. [Methods] Sixty cases with malignant serosal cavity effusion were randomly divided into two groups. Patients in observation group （n=30） re- ceived intracavitary administration of rAd-p53×2 （1×10^12vp per piece）,cisplatin 60mg 72h later intraperitoneal injection weekly for 2 weeks, then thermotherapy was operated twice a week, a total of 8 times underwent. Patients in control group （n=30） were given the same regimens as observation group except rAd-p53. [Results] The response rate （CR＋ PR） of observation group and control group was 86.7% and 60.0% respectively （P=0.01）. The quality of life improvement rate in observation group was significantly higher than that in control group （70% vs 30%, P=0.006）.The immunity of patients in observation group was unimpaired. The unique toxicity of observation group was transient fever.[Conclusion] rAd-p53 combined with chemotherapy and local thennotherapy for malignant serosal cavity effusion is safe and effective, and can improve the quality of life.

关 键 词：重组人P53腺病毒注射液 恶性浆膜腔积液 化疗 局部热疗 

分 类 号：R730.5[医药卫生—肿瘤] R730.6[医药卫生—临床医学]